Latest Breaking News On - Aurinia pharmaceuticals inc - Page 5 : comparemela.com

Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results

Achieved $50.3 million in total net revenue and $48.1 million in net product revenue for the first quarter of 2024, representing year over year growth of approximately 46% and 40% respectively, and.

Aurinia Pharmaceuticals Files SEC Report

Aurinia Pharmaceuticals (AUPH) has released an update. Aurinia Pharmaceuticals Inc. has filed a current report with the SEC, indicating routine cor.

Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month

In recognition of Lupus Awareness Month, Aurinia Pharmaceuticals Inc. , today announced several initiatives to improve understanding of the seriousness of lupus nephritis and the need for frequent.

The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program

New data showing sustained complete renal response with LUPKYNIS through three years Monthly kidney function assessment no longer required after first year…

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Short Interest Down 6.9% in April